Clinical Trial Update: EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on EPO906 therapy for advanced ovarian, fallopian tube, or primary peritoneal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• EPO906

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Ovarian Neoplasms, Peritoneal Neoplasms | Phase 2 | Status: COMPLETED